Pharmaceutical giant Novartis has agreed to pay more than $422 million in criminal fines and a global settlement of a spate of whistleblower lawsuits to resolve allegations that it engaged in illegal marketing practices, including the alleged payment of kickbacks to health care providers to induce them to prescribe Novartis drugs.

U.S. Attorney Zane Memeger said Novartis Pharmaceuticals Corp. — the U.S. subsidiary of Novartis AG in Switzerland — has agreed to pay a criminal fine and forfeiture of $185 million, and also agreed to pay $237.5 million to resolve civil liabilities for its off-label marketing of six drugs.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]